24/7 Market News Snapshot 02 April, 2025 – GRI Bio, Inc. Common Stock (NASDAQ:GRI)

DENVER, Colo., 02 April, 2025 (247marketnews.com) – (NASDAQ:GRI) are discussed in this article.
GRI Bio, Inc. (NASDAQ:GRI), a clinical-stage biotechnology firm focused on combating inflammatory, fibrotic, and autoimmune diseases, has recently made headlines following a significant public offering that raised approximately $5 million before expenses. The offering, which included 1,388,888 shares of common stock at a price of $3.60 per share, was well-received and facilitated by H.C. Wainwright & Co. as the exclusive placement agent. This capital infusion also includes warrants that could yield up to an additional $13.3 million if fully exercised, underscoring the company’s strategy to enhance shareholder value and advance its robust pipeline of innovative therapies.

Despite the positive fundraising news, GRI’s shares have faced a notable downturn in the market. Recently, the stock opened at $2.17 but has declined sharply by approximately 15.79%, now trading at $1.70 amid increased trading volume of 2.45 million shares. This volatility may reflect broader market conditions or responses to company-specific developments. Investors are advised to keep a close watch on key support levels as a breach below these could trigger further selling pressure.

The proceeds from the public offering are earmarked to accelerate the development of GRI’s lead program, GRI-0621, an oral therapy targeting idiopathic pulmonary fibrosis, and to explore new therapeutics from its proprietary library of over 500 compounds. GRI Bio is committed to pushing the boundaries in the treatment of chronic diseases characterized by inflammation and fibrosis, aspiring to restore immune system balance through its innovative approaches. As the company navigates its path post-offering, it remains focused on fostering scientific advancements that aim to improve patient outcomes in underserved areas of healthcare.

Related news for (GRI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.